UnknownNot Applicable

Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR

China55 participantsStarted 2019-12-01

Plain-language summary

using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2\* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular volume(ECV) to evaluate the respective changes before and after anthracycline chemotherapy.

Who can participate

Age range8 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All chemotherapy naive patients whose biopsy results show high grade osteosarcoma undergoing an anthracycline agent as part of their chemotherapy regimen * Informed consent has been signed Exclusion Criteria: * Strict contraindications to contrast-enhanced cardiac magnetic resonance imaging * Underlying heart disease:myocardial infarction, heart failure, valvular disease or cardiomyopathy * Acute or chronic kidney failure

What they're measuring

Completion of chemotherapy with anthracycline drugs

Timeframe: Through study completion, an average of 6 months.

Trial details

NCT IDNCT04461223

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-01

Contact for this trial

ELOY YIN WANG, Master

+8613588721020 eloy_yw@zju.edu.cn

View on ClinicalTrials.gov More Cardiotoxicity trials